Treatment of COVID-19 Vaccine-triggered Migraine

A 55-year-old woman with a long history of chronic migraines saw her symptoms worsen after getting a COVID-19 mRNA vaccine. Normally, her migraines were manageable with topiramate and sertraline. Despite medication adjustments, her pain escalated, scoring a 9 on the Visual Analogue Scale (VAS).

The underlying mechanisms of how SARS-CoV-2 impacts the nervous system remain unclear. Research suggests that the virus can invade the nervous system and trigger headaches by causing inflammation and vascular changes. Headache and loss of smell (anosmia) are thought to be linked to this direct neural invasion.

Calcitonin gene-related peptide (CGRP) is key in migraine pathophysiology, involved in pain transmission and inflammation. Elevated levels of interleukin (IL)-6 and tumor necrosis factor alpha (TNF-a), common in COVID-19, also increase CGRP, influencing symptoms like cough, fever, and pain.

Studies have found structural similarities between CGRP receptors and SARS-CoV-2 spike proteins, suggesting a potential link to persistent post-COVID headaches. Treatments with CGRP monoclonal antibodies (mAb) have shown promise in reducing such persistent headaches.

Preventive migraine medications like Aimovig (erenumab-aooe), Vyepti (eptinezumab-jjmr), Ajovy (fremanezumab-vfrm), and Emgality (galcanezumab-gnlm) work by either obstructing the CGRP receptor or neutralizing the CGRP protein itself. These medications belong to a category of biologic drugs known as monoclonal antibodies. While injections such as Aimovig, Ajovy, Vyepti, and Emgality are approved for both chronic and episodic migraines, Nurtec is an oral medication approved for both migraine prevention and acute treatment.

The new study from Istanbul demonstrated that CGRP mAb treatment could improve headaches induced by COVID-19 vaccination. Concurrent studies are investigating the use of CGRP antagonists for treating respiratory complications related to COVID-19, suggesting not just their safety but also their potential for clinical improvement.


REFERENCES

Duman SC, Özkan E, Özdemir YG. Treatment of COVID-19 Vaccine Resistant Migraine Attack with CGRP Monoclonal Antibody: A Case Report. Noro Psikiyatr Ars. 2023 Aug 12;60(3):292–4. doi: 10.29399/npa.28266. PMCID: PMC10461765. 

Yapici-Eser H, Koroglu YE, Oztop-Cakmak O, Keskin O, Gursoy A, Gursoy-Ozdemir Y. Neuropsychiatric symptoms of COVID-19 explained by SARS-CoV-2 proteins'mimicry of human protein ınteractions. Front Hum Neurosci. 2021;15:656313.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more